Endogenous antibody responsiveness to epidermal growth factor receptor is associated with immunoglobulin allotypes and overall survival of patients with glioblastoma

Details

• Personal Author:
  Black L ; Butler MA ; Carreon T ; Kaur N ; Kistner-Griffin E ; Namboodiri AM ; Pandey JP ; Radwan FF ; Ruder, Avima M.
• Description:
  Background. Immunoglobulin gamma marker (GM) and kappa marker (KM) allotypes, hereditary antigenic determinants of gamma and kappa chains, respectively, have been shown to be associated with immunity to a variety of self and nonself antigens, but their possible contribution to immunity to the tumor-associated antigens epidermal growth factor receptor (EGFR) and EGFR variant (v)III has not been evaluated. The aim of the present investigation was to determine whether the interindividual variation in endogenous antibody responsiveness to EGFR and EGFRvIII is associated with particular GM, KM, and Fcgamma receptor (FcgammaR) genotypes and whether antibody levels were associated with the overall survival of patients with glioblastoma. Methods. A total of 126 Caucasian participants with glioblastoma were genotyped for several GM, KM, and FcgammaR alleles and characterized for IgG antibodies to EGFR and EGFRvIII antigens. Results. The anti-EGFR antibody levels associated with GM 3/3 homozygotes and GM 3/17 heterozygotes were similar (15.9 vs 16.4 arbitrary units [AU]/microL) and significantly lower than those associated with GM 17/17 homozygotes (19.6 AU/microL; nominal P = .007). Participants homozygous for the GM 21 allele also had significantly higher levels of anti-EGFR antibodies than GM 5/5 homozygotes and GM 5/21 heterozygotes (20.1 vs 16.0 and 16.3 AU/microL; nominal P = .005). Similar associations were found with immune responsiveness to EGFRvIII. Higher anti-EGFR and anti-EGFRvIII antibody levels were associated with enhanced overall survival (16 vs 11 mo, nominal P = .038 and 20 vs 11 mo, nominal P = .004, respectively). Conclusions. GM allotypes contribute to humoral immunity to EGFR in glioblastoma. [Description provided by NIOSH]
• Subjects:
  Antibodies Antigens Biomarkers Genetics Growth Immune System Neoplasms Nervous System Nervous System Diseases Occupational Health Safety

  More +
• Keywords:
  Antibody-response Brain-tumors Cancer Genes Genetic-factors Growth-factors Humans Immune-reaction Immune-system Immunoglobulins Oncogenic-agents Survival-rate Tumors

  More +
• ISSN:
  1522-8517
• Document Type:
  Text
• Genre:
  Journal Article
• Place as Subject:
  Ohio ; OSHA Region 4 ; OSHA Region 5 ; South Carolina
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Division:
  DART - Division of Applied Research and Technology ; DSHEFS - Division of Surveillance, Hazard Evaluations, and Field Studies
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Volume:
  17
• Issue:
  5
• NIOSHTIC Number:
  nn:20045270
• Citation:
  Neuro-Oncology 2015 May; 17(5):678-684
• Contact Point Address:
  Janardan P. Pandey, PhD, Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425-2230
• Email:
  pandeyj@musc.edu
• Federal Fiscal Year:
  2015
• Peer Reviewed:
  True
• Source Full Name:
  Neuro-Oncology
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:68046a27df05c92de248538069893f3ed043477679bcdb8cb367a47a907ab98d5a2a5cab92979d6e964b4fa8d816ddec519c0a3fc837eb3614fa5c4a8aba3426
• Download URL:
  https://stacks.cdc.gov/view/cdc/200738/cdc_200738_DS1.pdf
• File Type:
  [PDF - 144.90 KB ]